This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Di Lenarda, A. Search for Related Content PubMed PubMed Citation Articles by Di Lenarda, A.

Long-term effects of carvedilol in idiopathic dilated cardiomyopathy with persistent left ventricular dysfunction despite chronic metoprolol

Andrea Di Lenarda, MD^*, Gastone Sabbadini, MD, Luca Salvatore, MD^*, Gianfranco Sinagra, MD^*, Luisa Mestroni, MD, FACC, Bruno Pinamonti, MD^*, Dario Gregori, PhD, Fulvio Ciani, MD^||, Aureo Muzzi, MD^*, Silvio Klugmann, MD^*, Fulvio Camerini, MD^* The Heart-Muscle Disease Study Group

^* Department of Cardiology, Ospedale Maggiore, Trieste, Italy
Department of Internal Medicine and Geriatrics, University of Trieste, Trieste, Italy
International Center for Genetic Engineering and Biotechnologies, Area Science Park, Trieste, Italy
Department of Statistics, University of Trieste, Trieste, Italy
^|| Respiratory Physiopathology Service, Ospedale Santorio, Trieste, Italy

View larger version (14K): [in a new window]   Figure 1 Time-dependent improvement of left ventricular ejection fraction (LVEF) with carvedilol (n = 14, black circles) or metoprolol (n = 16, open circles) in dilated cardiomyopathy patients with persistent left ventricular dysfunction despite chronic optimum treatment including angiotensin-converting enzyme inhibitors and metoprolol. *p = 0.033, 12 months vs. baseline carvedilol; p = 0.046, 12 months carvedilol vs. metoprolol.

View larger version (17K): [in a new window]   Figure 2 Effects of 12-month carvedilol (n = 14, black bars) or metoprolol (n = 16, open bars) treatment on left ventricular (LV) remodeling in dilated cardiomyopathy patients with persistent LV dysfunction despite chronic optimum treatment including angiotensin-converting enzyme inhibitors and metoprolol. *p = 0.053, 12 months carvedilol vs. metoprolol; p = 0.047, 12 months carvedilol vs. metoprolol. LVEDV = LV end-diastolic volume; LVESV = LV end-systolic volume.